Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cushing’s Syndrome Therapeutics Pipeline Demonstrates Positive Clinical Trial Results By: AB Newswire January 16, 2018 at 19:07 PM EST Cushing’s Syndrome Therapeutics Pipeline AnalysisCushing’s syndrome currently exhibits a growing pipeline with 13 drug candidates, P&S Market Research Orphan drug designations from the European Medicines Agency (EMA) is the one of the drivers for the development of pipeline drugs of Cushing’s syndrome. Majority of the pipeline drug candidates are being developed using the oral route of administration. Osilodrostat which is being developed by the Novartis AG is in the Phase III stage of development for the treatment of Cushing’s syndrome.Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=cushing-syndrome-therapeutics-pipeline-analysisThe existing drugs that are developed by the various pharmaceutical companies for the treatment of the disease have demonstrated positive clinical trial results, which in-turn is supporting their further development. For instance, Osilodrostat which is being developed by the Novartis AG demonstrated efficacy and well tolerated in the Phase II proof of concept study for the treatment of the Cushing’s syndrome.Download Report Sample at: https://www.psmarketresearch.com/market-analysis/cushing-syndrome-therapeutics-pipeline-analysis/report-sampleThe drug development process involves specific target such as steroid 11-beta-hydroxylase, which is the probable mechanism of action for the treatment of Cushing’s syndrome. Thus, this specific targeted therapy provides opportunities to the companies for better and targeted drug development. Some of the players developing drugs for the treatment of Cushing’s syndrome include Novartis AG, AstraZeneca Plc, Cyclacel Pharmaceuticals, Inc., and Angion Biomedica Corp.Cushing’s Syndrome Therapeutics Pipeline AnalysisBy PhaseBy Molecule TypeBy Route of AdministrationBy Company About P&S Market ResearchP&S Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries.With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our publication. Our research assists our client in identifying new and different windows of opportunity and frame informed and customized strategies for expansion in different regions.Media ContactCompany Name: P&S Market ResearchContact Person: AbhishekEmail: Send EmailPhone: +1-888-778-7886Address:347 5th Ave. #1402- 210 City: New York CityState: New YorkCountry: United StatesWebsite: https://www.psmarketresearch.com/industry-report/pharmaceuticals Source: www.abnewswire.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Cushing’s Syndrome Therapeutics Pipeline Demonstrates Positive Clinical Trial Results By: AB Newswire January 16, 2018 at 19:07 PM EST Cushing’s Syndrome Therapeutics Pipeline AnalysisCushing’s syndrome currently exhibits a growing pipeline with 13 drug candidates, P&S Market Research Orphan drug designations from the European Medicines Agency (EMA) is the one of the drivers for the development of pipeline drugs of Cushing’s syndrome. Majority of the pipeline drug candidates are being developed using the oral route of administration. Osilodrostat which is being developed by the Novartis AG is in the Phase III stage of development for the treatment of Cushing’s syndrome.Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=cushing-syndrome-therapeutics-pipeline-analysisThe existing drugs that are developed by the various pharmaceutical companies for the treatment of the disease have demonstrated positive clinical trial results, which in-turn is supporting their further development. For instance, Osilodrostat which is being developed by the Novartis AG demonstrated efficacy and well tolerated in the Phase II proof of concept study for the treatment of the Cushing’s syndrome.Download Report Sample at: https://www.psmarketresearch.com/market-analysis/cushing-syndrome-therapeutics-pipeline-analysis/report-sampleThe drug development process involves specific target such as steroid 11-beta-hydroxylase, which is the probable mechanism of action for the treatment of Cushing’s syndrome. Thus, this specific targeted therapy provides opportunities to the companies for better and targeted drug development. Some of the players developing drugs for the treatment of Cushing’s syndrome include Novartis AG, AstraZeneca Plc, Cyclacel Pharmaceuticals, Inc., and Angion Biomedica Corp.Cushing’s Syndrome Therapeutics Pipeline AnalysisBy PhaseBy Molecule TypeBy Route of AdministrationBy Company About P&S Market ResearchP&S Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries.With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our publication. Our research assists our client in identifying new and different windows of opportunity and frame informed and customized strategies for expansion in different regions.Media ContactCompany Name: P&S Market ResearchContact Person: AbhishekEmail: Send EmailPhone: +1-888-778-7886Address:347 5th Ave. #1402- 210 City: New York CityState: New YorkCountry: United StatesWebsite: https://www.psmarketresearch.com/industry-report/pharmaceuticals Source: www.abnewswire.com